Project title: Engineering γδT cells to target oncogenic hubs (P15)

• Subject Area: Hematology, Oncology ; Immunology
• Term: since 2021
• Project identifier: Deutsche Forschungsgemeinschaft (DFG) - Project number 441891347

We aim to harness γδ T cells for the treatment of BRAF-mutated colorectal cancer (CRC). In Aim 1, we will investigate how BRAF oncogenic signalling regulates the expression of γδ T-cell ligands and identify targetable molecules using pharmacological BRAF inhibition. In Aim 2, we will explore how BRAF signalling influences the tumour microenvironment and identify ways to overcome physical barriers limiting γδ T-cell infiltration. In Aim 3, we will engineer pro-infiltrating γδ T cells with enhanced anti-tumour activity. Our long-term goal is to develop combination therapies that improve γδ T-cell-mediated tumour control in CRC.

• DFG Programme: Collaborative Research Centres
• Subproject of: SFB 1479: Oncogene-driven immune escape (OncoEscape)
• Applicant Institution: Albert-Ludwigs-Universität Freiburg
• Project Head: Professorin Susana Minguet, Ph.D.